CellbxHealth board expects to be EBITDA positive in 2028

CelLBxHealth PLC has indicated that it anticipates achieving EBITDA positivity by 2028, as part of its ongoing strategic transformation and operational optimization. The company, which has repositioned itself toward a partner-led, capital-efficient business model, continues to focus on expanding the adoption of its circulating tumor cell (CTC) platform through key partnerships with diagnostics firms such as QIAGEN, Roche Diagnostics, and Illumina.

The board reaffirmed its 2026 revenue target of £2.1 million, a 50% increase from 2025, reflecting long-term potential of its technology and market opportunity. While the company reported lower revenue in the second half of 2025, it has implemented significant operational efficiencies and strengthened its leadership and governance structures.

With a clear focus on sustainable growth and strong corporate governance, CelLBxHealth remains committed to delivering long-term value to shareholders. The board is currently in the process of recruiting a new CEO, with the executive chairman emphasizing that operations will remain stable during the transition.